Navjot Pabla is an Assistant Professor in the College of Pharmacy and Comprehensive Cancer Center at The Ohio State University. He has a longstanding interest in exploring the biological functions of protein kinases. Protein kinases control most cellular processes and deregulation of protein kinase activity is frequently associated with human disorders. Importantly, protein kinases are druggable targets as exemplified by the development and FDA approval of more than 50 small molecule kinase inhibitors, mostly for cancer therapy. His research is focused on understanding how protein kinases influence the pathogenesis of acute kidney injury with the long-term goal to identify small molecule inhibitors for potential clinical translation.